Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 438, 913 (15 December 2005) | doi:10.1038/438913b; Published online 14 December 2005
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
nature jobs
Copy Editor
- Indegene Lifesystems Pvt. Ltd
- Bengaluru 560 071 India
System Engineer (Mechanical)
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
In brief
British biotechnology company Astex Therapeutics last week announced a deal with Swiss drug giant Novartis that is potentially worth US$500 million. Under the agreement, Novartis will pay $25 million to secure the global licensing rights to Astex's anticancer drug AT9311.
To read this story in full you will need to login or make a payment (see right).

